IBDEI0RY ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,13109,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13109,1,3,0)
 ;;=3^DM Type 1 w/ Diabetic Autonomic Polyneuropathy
 ;;^UTILITY(U,$J,358.3,13109,1,4,0)
 ;;=4^E10.43
 ;;^UTILITY(U,$J,358.3,13109,2)
 ;;=^5002607
 ;;^UTILITY(U,$J,358.3,13110,0)
 ;;=E10.59^^53^585^4
 ;;^UTILITY(U,$J,358.3,13110,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13110,1,3,0)
 ;;=3^DM Type 1 w/ Circulatory Complications
 ;;^UTILITY(U,$J,358.3,13110,1,4,0)
 ;;=4^E10.59
 ;;^UTILITY(U,$J,358.3,13110,2)
 ;;=^5002612
 ;;^UTILITY(U,$J,358.3,13111,0)
 ;;=E10.618^^53^585^5
 ;;^UTILITY(U,$J,358.3,13111,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13111,1,3,0)
 ;;=3^DM Type 1 w/ Diabetic Arthropathy
 ;;^UTILITY(U,$J,358.3,13111,1,4,0)
 ;;=4^E10.618
 ;;^UTILITY(U,$J,358.3,13111,2)
 ;;=^5002614
 ;;^UTILITY(U,$J,358.3,13112,0)
 ;;=E10.621^^53^585^7
 ;;^UTILITY(U,$J,358.3,13112,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13112,1,3,0)
 ;;=3^DM Type 1 w/ Diabetic Foot Ulcer
 ;;^UTILITY(U,$J,358.3,13112,1,4,0)
 ;;=4^E10.621
 ;;^UTILITY(U,$J,358.3,13112,2)
 ;;=^5002616
 ;;^UTILITY(U,$J,358.3,13113,0)
 ;;=E10.622^^53^585^11
 ;;^UTILITY(U,$J,358.3,13113,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13113,1,3,0)
 ;;=3^DM Type 1 w/ Skin Ulcer
 ;;^UTILITY(U,$J,358.3,13113,1,4,0)
 ;;=4^E10.622
 ;;^UTILITY(U,$J,358.3,13113,2)
 ;;=^5002617
 ;;^UTILITY(U,$J,358.3,13114,0)
 ;;=E10.65^^53^585^10
 ;;^UTILITY(U,$J,358.3,13114,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13114,1,3,0)
 ;;=3^DM Type 1 w/ Hyperglycermia
 ;;^UTILITY(U,$J,358.3,13114,1,4,0)
 ;;=4^E10.65
 ;;^UTILITY(U,$J,358.3,13114,2)
 ;;=^5002623
 ;;^UTILITY(U,$J,358.3,13115,0)
 ;;=E10.39^^53^585^9
 ;;^UTILITY(U,$J,358.3,13115,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13115,1,3,0)
 ;;=3^DM Type 1 w/ Diabetic Ophthalmic Complications NEC
 ;;^UTILITY(U,$J,358.3,13115,1,4,0)
 ;;=4^E10.39
 ;;^UTILITY(U,$J,358.3,13115,2)
 ;;=^5002603
 ;;^UTILITY(U,$J,358.3,13116,0)
 ;;=E66.3^^53^585^45
 ;;^UTILITY(U,$J,358.3,13116,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13116,1,3,0)
 ;;=3^Overweight
 ;;^UTILITY(U,$J,358.3,13116,1,4,0)
 ;;=4^E66.3
 ;;^UTILITY(U,$J,358.3,13116,2)
 ;;=^5002830
 ;;^UTILITY(U,$J,358.3,13117,0)
 ;;=E89.1^^53^585^49
 ;;^UTILITY(U,$J,358.3,13117,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13117,1,3,0)
 ;;=3^Postprocedural Hypoinsulinemia
 ;;^UTILITY(U,$J,358.3,13117,1,4,0)
 ;;=4^E89.1
 ;;^UTILITY(U,$J,358.3,13117,2)
 ;;=^5003036
 ;;^UTILITY(U,$J,358.3,13118,0)
 ;;=H40.9^^53^586^9
 ;;^UTILITY(U,$J,358.3,13118,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13118,1,3,0)
 ;;=3^Glaucoma,Unspec
 ;;^UTILITY(U,$J,358.3,13118,1,4,0)
 ;;=4^H40.9
 ;;^UTILITY(U,$J,358.3,13118,2)
 ;;=^5005931
 ;;^UTILITY(U,$J,358.3,13119,0)
 ;;=H26.9^^53^586^5
 ;;^UTILITY(U,$J,358.3,13119,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13119,1,3,0)
 ;;=3^Cataract,Unspec
 ;;^UTILITY(U,$J,358.3,13119,1,4,0)
 ;;=4^H26.9
 ;;^UTILITY(U,$J,358.3,13119,2)
 ;;=^5005363
 ;;^UTILITY(U,$J,358.3,13120,0)
 ;;=H10.9^^53^586^8
 ;;^UTILITY(U,$J,358.3,13120,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13120,1,3,0)
 ;;=3^Conjunctivitis,Unspec
 ;;^UTILITY(U,$J,358.3,13120,1,4,0)
 ;;=4^H10.9
 ;;^UTILITY(U,$J,358.3,13120,2)
 ;;=^5004716
 ;;^UTILITY(U,$J,358.3,13121,0)
 ;;=H11.32^^53^586^6
 ;;^UTILITY(U,$J,358.3,13121,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13121,1,3,0)
 ;;=3^Conjunctival Hemorrhage,Left Eye
 ;;^UTILITY(U,$J,358.3,13121,1,4,0)
 ;;=4^H11.32
 ;;^UTILITY(U,$J,358.3,13121,2)
 ;;=^5004783
 ;;^UTILITY(U,$J,358.3,13122,0)
 ;;=H11.31^^53^586^7
 ;;^UTILITY(U,$J,358.3,13122,1,0)
 ;;=^358.31IA^4^2
